About us

Naveen N. Anand, M Pharma,PhD, MBA
Chief Executive Officer

Dr. Naveen Anand is the recently appointed CEO of Pan-Provincial Vaccine Enterprise Inc. PREVENT), a NCE-CECR funded Center for Commercialization of Vaccines, structured as a Not-for-Profit Corporation in Saskatoon, Saskatchewan.

A Pharmacist by training, Dr. Anand received his PhD from the University of Cambridge in the UK and a MBA from the University of Toronto, Canada. He started his work career as a Research Associate at the Institute of Biological Sciences of the National Research Council of Canada in Ottawa. Subsequently, Dr. Anand was recruited to Aventis Pasteur in Toronto, initially as a Research Scientist, transitioning to  commercial operations, culminating in managing the function of “New Products and Markets Development” for the Oncology business unit.

In December of 1999, Dr. Anand joined Procyon Biopharma Inc. (now Ambrilia Biopharma), a Montreal based Biotechnology Company, as the Vice President of Business Development, in charge of all licensing activities as well as external relations with investors (IR & PR activities). As an Officer of the Company and member of the Executive Management Committee, his primary focus was on business and strategy. Subsequently,(until September 2004), he served as Vice-president of Business Development for Shire Biologics (a fully integrated vaccine company headquartered in Canada), which was then a part of the UK based Shire group of companies. Dr. Anand was responsible for all licensing, Business Development and prospecting activities for Shire Biologics on a global basis. In addition to these activities, he managed the day-to-day operations of a strategically important marketing alliance (with a European Vaccine company - Berna Biotech) and international sales ensuing from this alliance.  He was also part of the Executive Management which commissioned the expansion of the Flu vaccine plant from 3 million doses to a facility with potential for 50 million doses, as well as managing the pandemic flu vaccine contract with the Government of Canada.

After the buyout of Shire Biologics by ID Biomedical of Canada (now part of GSK Biologics) in September of 2004, Dr. Anand has worked as a consultant to Biotechnology/Life Sciences companies. In this capacity, he has consulted for both ID Biomedical of Quebec and Hybridon Inc. (now Idera Pharma), a biotechnology company based in Cambridge, MA.  Other corporate clients include a start up company in Glasgow, Scotland, a medical device/nanotechnology company, based in London, Ontario and a couple of Indian Pharmaceutical companies interested in sourcing products in North America for both domestic and international markets.

Dr. Anand has worked contractually with the Office of Technology Transfer, McGill University in Montreal, Quebec on activities were directed at helping commercialize technologies arising out of the research at the University in the Life Sciences area, particularly those which were relatively more advanced and which required a high level of interaction with commercial partners.

Dr. Anand has also worked with the International Finance Corporation (IFC), a part of the World Bank Group, headquartered in Washington D.C. as a Life Sciences Industry Specialist on projects in China, India and Latin America. His activities at the IFC were focused on conducting analysis and due diligence on both technical and business activities of potential investment opportunities, including facilities and infrastructure of Life Science organizations. Additional activities included initial evaluation of opportunities and support of business development activities in conjunction with life sciences investment team in Washington and local offices. This experience gave him valuable insight and connectivity with international developmental organizations including such programs as the AMC (Advance Market Commitment) programs for Pneumococcal vaccine, ongoing at the World Bank.

Phone: (306) 966-2551; n.anand@usask.ca


Did you know?
image of E. coli bacteria

Escherichia coli (E. coli), is a bacterium commonly found in the lower intestine of warm-blooded animals. Most E. coli strains are harmless and are part of the normal beneficial flora of the gut, but some, such as serotype O157:H7, can cause serious food poisoning in humans. Ingestion of contaminated water or food is the usual causes of illness from E. coli.

BACKGROUNDER

Immunization:
Inoculation and Vaccination

Inoculation (also known as variolation) was introduced to the west by Lady Mary Wortley Montagu (1689-1762), who witnessed inoculation being
portrait of lady
practiced by physicians in Constantinople,[12] and was greatly impressed:[13] she had lost a brother to smallpox and bore facial scars from the disease herself. In 1718 she had the embassy surgeon inoculate her son, and in 1721, after returning to England, had her daughter inoculated[14]. In 1722 the Prince of Wales' daughters received inoculations[16].

The practice of inoculation slowly spread amongst the royal families of Europe, followed by general adoption amongst the rest of the population. Given the severe consequences of smallpox in Europe in the 18th century, many parents felt that the benefits outweighed the risks and so inoculated their children.[21] [22]

... more